{"id":"NCT01330316","sponsor":"Boehringer Ingelheim","briefTitle":"A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients","officialTitle":"A Phase III, Open-label Study of Once Daily BI 201335 240 mg for 24 Weeks in Combination With Pegylated interferon-a (PegIFN) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN / RBV Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2011-04-06","resultsPosted":"2015-07-31","lastUpdate":"2016-06-30"},"enrollment":119,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"BI 201335","otherNames":[]},{"type":"DRUG","name":"PegIFN/RBV","otherNames":[]}],"arms":[{"label":"BI 201335 for 24 weeks","type":"EXPERIMENTAL"}],"summary":"The objective of this trial is to collect evidence for the safety and efficacy of 24 weeks of treatment with BI 201335 240 mg in combination with 24 or 48 weeks of Pegylated Interferon (PegIFN) and ribavirin (RBV) in treatment experienced patients who have been withdrawn from PegIFN and RBV treatment due to lack of efficacy in the 1220.7, 1220.30 and 1220.47 trials.","primaryOutcome":{"measure":"Sustained Virological Response (SVR): Plasma HCV RNA Level < 25 IU/mL","timeFrame":"12 weeks post treatment, up to 60 weeks","effectByArm":[{"arm":"Relapse","deltaMin":95.3,"sd":null},{"arm":"Non-relapse","deltaMin":54.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":87,"countries":["United States","Austria","Belgium","Canada","France","Germany","Japan","Portugal","Romania","Russia","South Korea","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["26572686"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":43},"commonTop":["Nausea","Pruritus","Diarrhoea","Rash","Anaemia"]}}